Get the Stockscreener App
29.46
0.97%
-0.29
After Hours:
29.46
Xenon Pharmaceuticals Inc stock is traded at $29.46, with a volume of 1.06M.
It is down -0.97% in the last 24 hours and down -21.69% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$29.75
Open:
$30.22
24h Volume:
1.06M
Relative Volume:
1.22
Market Cap:
$2.26B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-10.75
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-6.27%
1M Performance:
-21.69%
6M Performance:
-31.73%
1Y Performance:
-23.22%
1-Day Range:
$29.43
$30.46
1-Week Range:
$29.38
$31.30
52-Week Range:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
29.46 | 2.41B | 13.17M | -199.06M | -156.53M | -2.74 |
|
ONC
Beigene Ltd Adr
|
238.31 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.00 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.26 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.61 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Xenon Pharmaceuticals’ SWOT analysis: neurological drug stock faces pivotal year - Investing.com India
Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings - Defense World
XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
What is William Blair’s Estimate for XENE FY2025 Earnings? - Defense World
Wedbush Equities Analysts Cut Earnings Estimates for XENE - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Evercore ISI - Defense World
HC Wainwright Issues Optimistic Outlook for XENE Earnings - Defense World
How To Trade (XENE) - news.stocktradersdaily.com
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Chardan Capital Reiterates “Buy” Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Needham & Company LLC Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00 - Defense World
Wells Fargo & Company Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by StockNews.com - Defense World
Evercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Xenon signals Phase 3 epilepsy readout in early 2026 with expanded pipeline advancements - MSN
Xenon Pharmaceuticals to Present at 2025 RBC Healthcare Conference - TipRanks
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Xenon CEO to Showcase Revolutionary Late-Stage Epilepsy Treatment: Key Updates Coming at RBC Conference - Stock Titan
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Ra - GuruFocus
XENE: Evercore ISI Group Initiates Coverage with 'Outperform' Rating | XENE Stock News - GuruFocus
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday - Insider Monkey
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript - Insider Monkey
XENE: Wells Fargo Adjusts Price Target for Xenon Pharmaceuticals - GuruFocus
Xenon Pharmaceuticals (XENE) Price Target Adjusted by Analyst | - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down After Analyst Downgrade - Defense World
XENE: HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
XENE: RBC Capital Adjusts Price Target as Xenon Pharmaceuticals Faces Timeline Shift | XENE Stock News - GuruFocus
XENE: Analyst Reaffirms Buy Rating with Price Target of $55 | XE - GuruFocus
XENE Price Target Revised Following Earnings and Data Delay | XE - GuruFocus
XENE: Needham Adjusts Price Target on Xenon Pharmaceuticals | XE - GuruFocus
XENE: RBC Capital Lowers Xenon Pharmaceuticals Price Target | XE - GuruFocus
FOS-tering patience: Xenon moves azetukalner data to next year - BioWorld MedTech
Xenon Pharmaceuticals stock falls on delayed study results By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock falls on delayed study results - Investing.com Australia
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlight - GuruFocus
Xenon Pharmaceuticals Advances Clinical Programs Amid Financial Loss - TipRanks
Xenon Pharmaceuticals Reports Q1 2025 Results and Advances Clinical Pipeline - TipRanks
XENE: Xenon Advances Phase 3 Programs in Epilepsy and Psychiatry | XENE Stock News - GuruFocus
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings: EPS Loss of $0.83 Beats Estimate, Revenue Soars to $7.5 Million - GuruFocus
XENON PHARMACEUTICALS Earnings Results: $XENE Reports Quarterly Earnings - Nasdaq
Xenon Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):